AIDS Vaccine Moves to Clinical Trials
Posted by pozlife on August 30, 2006
A new multiprotein AIDS vaccine will be evaluated in humans for the first time, after its remarkable success in protecting monkeys from the disease. In studies conducted at the NCRR-funded Yerkes National Primate Research Center, the vaccine protected 96 percent of monkeys from developing AIDS for more than three years, providing better and longer protection than any other AIDS vaccine candidate to date. The vaccine has been under development since 1997 by Yerkes researcher Harriet Robinson and her colleagues at the National Institute of Allergy and Infectious Diseases and the Centers for Disease Control and Prevention. It was licensed for commercial use by GeoVax in 2004.
The new vaccine uses DNA to prime the immune response and a genetically modified “pox”-type virus to boost the immune response. Both vaccine components express noninfectious virus-like particles. Phase I clinical trials, conducted through the NIH-sponsored HIV Vaccine Trials Network, began in April 2006 at the University of Alabama at Birmingham, the University of Maryland, and St. Louis University. If successful, the vaccine would face at least four more years of clinical testing.